Innovation Pharmaceuticals Inc (IPIX)

[TheHound]

5-31-16 $CTIX ~ Cellceutix Corp. Due Diligence Report

------------------------------------------------------------------

$CTIX news

http://www.cellceutix.com/category/press-release/#sthash.ZHlr967e.dpbs

Latest PR's from Cellceutix:

Tues, 31 May 2016 ~ Cellceutix Releases Pharmacokinetics Data From Phase 2 Trial of Prurisol for Treating Psoriasis; Data Complements Efficacy Data Reported Last Week. Read more: http://cellceutix.com/cellceutix-releases-pharmacokinetics-data-from-phase-2-trial-of-prurisol-for-treating-psoriasis-data-complements-efficacy-data-reported-last-week/#sthash.3mPPOUnq.dpbs

Thurs, 26 May 2016 ~ Cellceutix Provides Additional Insight Into Successful Phase 2 Trial for Treating Psoriasis. Read more: http://cellceutix.com/cellceutix-provides-additional-insight-into-successful-phase-2-trial-for-treating-psoriasis/#sthash.fW5SLmz0.dpbs

Tues, 24 May 2016 ~ Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint. Read more: http://cellceutix.com/cellceutix-phase-2-trial-of-prurisol-for-mild-to-moderate-psoriasis-meets-primary-endpoint/

$CTIX filings - Perhaps the most important section

http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany


$CTIX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com




$CTIX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CTIX/company-info
Ticker: $CTIX
OTC Market Place: OTC Pink Current
CIK code: 0001355250
Company name: Cellceutix Corp.
Company website: http://www.cellceutix.com
Incorporated In: NV, USA

Additional $CTIX company information:

## source: Cellceutix

Business Description: Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol completed a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.

To find more information on completed and active Human Clinical Trials, please click the below link.

https://www.clinicaltrials.gov/ct2/results?term=cellceutix&Search=Search

$CTIX Share Structure

## source: otcmarkets.com

Market Value: $132,602,100 a/o Feb 09, 2016
Shares Outstanding: 118,500,536 a/o Oct 31, 2015
Float: Not Available
Authorized Shares: 300,000,000 a/o May 12, 2008
Par Value: 0.0001

Various $CTIX DD links

Cellceutix Corp. website - http://www.cellceutix.com
Company Email - [e-mail]
Management - http://cellceutix.com/team/
Product Pipeline - http://cellceutix.com/pipeline/
Recent News and Press Releases - http://finance.yahoo.com/q/h?s=CTIX+Headlines
SEC Filings - http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
Financials - http://www.otcmarkets.com/stock/CTIX/financials
Transfer Agent - http://www.westcoaststocktransfer.com/
Short Interest - http://www.otcmarkets.com/stock/CTIX/short-sales
Key Statistics - http://www.finance.yahoo.com/q/ks?s=CTIX+Key+Statistics
Insider Roster - http://www.finance.yahoo.com/q/ir?s=CTIX+Insider+Roster
Insider transactions - http://www.secform4.com/insider-trading/CTIX.htm
Income Statement - http://finance.yahoo.com/q/is?s=CTIX
Balance Sheet - http://www.finance.yahoo.com/q/bs?s=CTIX
Cash Flow - http://www.finance.yahoo.com/q/cf?s=CTIX+Cash+Flow&annual

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275

Current/Completed Human Trials

http://www.clinicaltrials.gov/ct2/results?term=cellceutix&Search=Search

1. Prurisol (Phase 1, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT02101216?term=cellceutix&rank=1

Prurisol (Phase 2, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT02494479?term=cellceutix&rank=2

2. Brilacidin-Oral Mucositis (Phase 2, Active, Recruiting): http://www.clinicaltrials.gov/ct2/show/NCT02324335?term=cellceutix&rank=3

3. Kevetrin (Phase 1, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=4

4. Brilacidin-ABSSSI (Phase 2, Successful Completion): http://www.clinicaltrials.gov/ct2/show/NCT02052388?term=cellceutix&rank=5